Post-Traumatic Stress Disorder (PTSD)
Conditions
Keywords
PTSD
Brief summary
A Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation (Prism), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD)
Detailed description
Prism is a software device intended for neurofeedback (NF) training (i.e. operant condition based on EEG signals, also known as EEG-biofeedback), to be used in combination with a standard computer and supported EEG hardware. For purposes of this training, information for feedback is derived and processed from several EEG channels. Prism provides visual and/or auditory signals that correspond to the patient's computed EEG signal, which serves as a surrogate indicator of achieving a state of reduced amygdala activity. The study is a Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation (Prism), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD). The study population will include subjects diagnosed with Post-Traumatic Stress Disorder (PTSD) from 1 year to 20 years after index trauma. The total expected enrollment is up to 100 subjects in one or more sites. The study's primary objective is to assess the safety and effectiveness of fifteen (15) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms.
Interventions
DEVICEPRISM
Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
Sponsors
GrayMatters Health Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
single-arm, open-label study
Eligibility
Sex/Gender
ALL
Age
22 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Ages 22 to 65 2. Any gender 3. Diagnosis of PTSD, established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) 4. 1 to 20 years since index trauma 5. Ability to give signed, informed consent 6. Normal or corrected-to-normal vision 7. Normal or corrected to normal hearing 8. Subject is able to adhere to the study schedule
Exclusion criteria
1. Have completed two or more full courses of trauma-focused therapy in the past (i.e., EMDR, Prolong Exposure Therapy, etc.), eligibility will be deemed upon the clinical judgment of the investigator. 2. Lifetime diagnosis for schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder 3. Any mood disorder and anxiety disorder according to DSM-5 (in addition to those described in Exclusion 2) that is the primary focus of treatment in the last 6 months prior to screening, as per the clinical judgment of the investigator 4. Lifetime diagnosis of autism, mental retardation at the discretion of the investigator. 5. Diagnosis of moderate or severe substance use disorder within the last 3 months of screening visit (as defined in DSM-5-substance use disorder) or at screening visit 6. Any prescribed Benzodiazepine which cannot be ceased for the duration of the study (with a washout period of at least 2 weeks prior to the first Prism training session) or which cannot be replaced with short-acting benzodiazepines that are taken only for sleeping during the night 7. Any psychotropic medication other than a stable dose of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs) 8. Any change in or initiation of- SSRIs or SNRIs antidepressants within the past 4 weeks. At the time of recruitment, subjects must have no intention of changing their medication or psychotherapy during the study duration 9. Any suicidal behavior in the past 1 year (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior) prior to screening and during the screening period 10. Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based PTSD psychotherapy (Cognitive Processing Therapy \[CPT\], Prolonged Exposure \[PE\], Eye Movement Desensitization and Reprocessing \[EMDR\]); continuation of established maintenance supportive therapy will be permitted 11. Any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury \[TBI\] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days) 12. Any unstable medical condition, as per the clinical judgement of the investigator 13. In process of establishing/changing governmental/institutional compensation payments for PTSD symptoms 14. Enrollment in another clinical study at screening or within 2 months prior to screening, or intended enrollment within the duration of this study 15. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinician Administered PTSD Scale (CAPS - 5) | Baseline visit (Week 1) and 3 month Follow-up visit | The primary objective of this study is to assess the proportion of subjects who demonstrate clinically meaningful improvement in the Clinician Administered PTSD Scale (CAPS - 5) score from Baseline to the 3 months follow-up visit. Clinically meaningful improvement is defined here as a 6-point reduction or more in the CAPS-5 score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PCL-5 response rate | Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit | To assess the proportion of subjects who demonstrate clinically meaningful improvement in the PTSD Checklist for DSM-5 (PCL-5). Clinically meaningful improvement is defined here as a 10-point reduction or more in the PCL-5 score |
| ERQ score | Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit | Change from baseline to Month 3 visit in ERQ score |
| PHQ-9 score | Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit | Change from baseline to Month 3 visit in PHQ-9 score |
| Clinical Global Impression (CGI) | Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit | Change from baseline to Month 3 visit in CGI score |
Other
| Measure | Time frame | Description |
|---|---|---|
| learning success of the EFP-based neurofeedback | through study completion, an average of 8 weeks | To quantify the learning success of the EFP-based neurofeedback (namely: learning volitional down-regulation of the Amyg-EFP signal, over time, during the EFP-NF training period) |
| Patient satisfaction survey | through study completion, an average of 5 month | To quantify patient satisfaction from the EFP-NF training using survey |
| Remission rate | Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit | To assess the Remission rate at post training visit (8-9 weeks) and at the 3 months follow-up visit |
| Abbreviated PCL (APCL) | through study completion, an average of 8 weeks | To assess the change in the score of the abbreviated PCL scale (APCL, assessed weekly during the EFP-NF training period) |
Countries
Israel, United States
Outcome results
None listed